Metabolic
Credibility 80
SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population-Based Cross-Sectional Study of Uptake of NICE Guidance.
October 4, 2026 · Diabetes, obesity & metabolism
Key takeaway
This study found that Black adults with type 2 diabetes were less likely to get important heart and kidney medications (SGLT2 inhibitors). This matters because these medicines protect our hearts and kidneys, and everyone in our community deserves access to them, regardless of background.
Why this matters for our communities
Research in metabolic helps close long-standing gaps in how Black and African American families are studied, diagnosed, and cared for. Use findings like this one to start informed conversations with your care team — not as a substitute for personal medical advice.
More in Metabolic
December 31, 2026"Sometimes it's the bullying": an exploratory qualitative study of church leaders' perceptions of dietary health of black American children and youth.Read December 31, 2026What unhealthy food and beverage advertisements appeal to- and promote obesity amongst- adolescent children in urban South Africa?Read December 6, 2026Program and Family Predictors of Retention and Weight Loss Among Black Youth in a Pediatric Weight Management Program.Read